Latest news
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Fri, 07 Aug 2026 19:00:00 GMTReal-world outcomes of first-line pembrolizumab plus chemotherapy in metastatic triple-negative breast cancer with central nervous system metastases: a multicenter cohort from Poland, the Czech Republic and Slovakia | Pieniążek | Reports of Practical Oncol - journals.viamedica.pljournals.viamedica.pl · Mon, 03 Aug 2026 14:02:58 GMTOlubukola Ayodele: "Trojan-Horse" Therapies in First-Line Metastatic Breast Cancer - OncodailyOncodaily · Mon, 03 Aug 2026 11:20:21 GMTDatroway Wins EU Approval for First-Line Metastatic Triple-Negative Breast Cancer - BioPharm InternationalBioPharm International · Fri, 31 Jul 2026 17:17:31 GMTDatroway approved in the EU as only TROP2-directed medicine with overall survival benefit for the 1st-line treatment of patients with metastatic TNBC who are not candidates for immunotherapy - AstraZenecaAstraZeneca · Fri, 31 Jul 2026 02:00:00 GMT